Literature DB >> 21719600

How I conduct a comprehensive chronic graft-versus-host disease assessment.

Paul A Carpenter1.   

Abstract

Since the National Institutes of Health Chronic Graft-Versus-Host Disease (cGVHD) Consensus Project in 2005, a need has emerged to evaluate cGVHD more methodically, not only to make a cGVHD diagnosis, but also to accurately classify individual organ and global organ severity, at baseline and in follow-up so that subjects participating in clinical trials may reliably be assigned an accurate response category irrespective of the evaluator. Even for patients not enrolled on a clinical trial, periodic complete cGVHD assessments can allow subtle manifestations to be detected, monitored carefully, and/or treated early with the goal of hopefully avoiding progression to highly morbid, difficult to treat, and quite often irreversible forms of cGVHD. Early feedback has been that the National Institutes of Health approach to diagnosis classification, staging, and response, as well as other new assessment tools, are too detailed and overly complex. This article tries to address many of these issues by describing how I conduct a comprehensive cGVHD assessment using a streamlined and reliable method that I use regularly within the constraints of a busy clinic.

Entities:  

Mesh:

Year:  2011        PMID: 21719600     DOI: 10.1182/blood-2011-04-314815

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  15 in total

Review 1.  How we treat chronic graft-versus-host disease.

Authors:  Mary E D Flowers; Paul J Martin
Journal:  Blood       Date:  2014-11-14       Impact factor: 22.113

Review 2.  Cutaneous graft-versus-host disease--clinical considerations and management.

Authors:  Peggy A Wu; Edward W Cowen
Journal:  Curr Probl Dermatol       Date:  2012-02-17

3.  Assessment of joint and fascia manifestations in chronic graft-versus-host disease.

Authors:  Yoshihiro Inamoto; Joseph Pidala; Xiaoyu Chai; Brenda F Kurland; Daniel Weisdorf; Mary E D Flowers; Jeanne Palmer; Sally Arai; David Jacobsohn; Corey Cutler; Madan Jagasia; Jenna D Goldberg; Paul J Martin; Steven Z Pavletic; Georgia B Vogelsang; Stephanie J Lee; Paul A Carpenter
Journal:  Arthritis Rheumatol       Date:  2014-04       Impact factor: 10.995

4.  How I assess comorbidities before hematopoietic cell transplantation.

Authors:  Mohamed L Sorror
Journal:  Blood       Date:  2013-01-25       Impact factor: 22.113

5.  Crowdsourcing to delineate skin affected by chronic graft-vs-host disease.

Authors:  Eric R Tkaczyk; Joseph R Coco; Jianing Wang; Fuyao Chen; Cheng Ye; Madan H Jagasia; Benoit M Dawant; Daniel Fabbri
Journal:  Skin Res Technol       Date:  2019-02-20       Impact factor: 2.365

6.  Poor agreement between clinician response ratings and calculated response measures in patients with chronic graft-versus-host disease.

Authors:  Jeanne M Palmer; Stephanie J Lee; Xiaoyu Chai; Barry E Storer; Mary E D Flowers; Kirk R Schultz; Yoshihiro Inamoto; Corey Cutler; Joseph Pidala; Mukta Arora; David A Jacobsohn; Paul A Carpenter; Steven Z Pavletic; Paul J Martin
Journal:  Biol Blood Marrow Transplant       Date:  2012-06-09       Impact factor: 5.742

7.  Prevalence of isolated joint involvement in chronic graft-versus-host disease: comment on the article by Inamoto et al.

Authors:  Zoya Kuzmina; Galen O Joe; Kristin Baird; Edward W Cowen; Haley B Naik; Seth M Steinberg; Lauren Curtis; Leora E Comis; Steven Z Pavletic
Journal:  Arthritis Rheumatol       Date:  2014-09       Impact factor: 10.995

Review 8.  Physical function and quality of life in patients with chronic GvHD: a summary of preclinical and clinical studies and a call for exercise intervention trials in patients.

Authors:  C Fiuza-Luces; R J Simpson; M Ramírez; A Lucia; N A Berger
Journal:  Bone Marrow Transplant       Date:  2015-09-14       Impact factor: 5.483

Review 9.  Current issues in chronic graft-versus-host disease.

Authors:  Gérard Socié; Jerome Ritz
Journal:  Blood       Date:  2014-06-09       Impact factor: 22.113

10.  A randomized phase 2 trial of pomalidomide in subjects failing prior therapy for chronic graft-versus-host disease.

Authors:  Lauren M Curtis; Alen Ostojic; David J Venzon; Noa G Holtzman; Filip Pirsl; Zoya J Kuzmina; Kristin Baird; Jeremy J Rose; Edward W Cowen; Jacqueline W Mays; Sandra A Mitchell; Laura Parsons-Wandell; Galen O Joe; Leora E Comis; Ann Berger; Iskra Pusic; Cody J Peer; William D Figg; Liang Cao; Robert Peter Gale; Frances T Hakim; Steven Z Pavletic
Journal:  Blood       Date:  2021-02-18       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.